Pfizer snaps up rights to commercialize diabetes GLP-1 in China
Looking to gain an edge as its broader obesity ambitions take shape, Pfizer has picked up the rights to a recently approved GLP-1 in China, unlocking an immediate commercial opportunity in type 2 diabetes with…
Read guide →